07/18/2021: Lab Alert: FDA Revokes EUA for Curative SARS-CoV-2 Assay

CDC's Laboratory Outreach Communication System (LOCS)

Audience: Individuals Performing COVID-19 Testing

Level: Laboratory Alert

On July 15, 2021, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) for the Curative SARS-CoV-2 Assay. Effective immediately, laboratories and testing sites should discontinue use of the Curative test.

In a letter to FDA dated June 16, 2021, Curative Inc. requested that the EUA for the Curative SARS-CoV-2 Assay be revoked effective July 15, 2021. The company stated that it was transitioning to the use of different EUA-authorized SARS-CoV-2 tests for the testing offered at its laboratories.

Refer to the FDA Letter of Revocation for more information.

Click this link and enter your email address to receive updates from the CDC Laboratory Outreach Communication System (LOCS).

Online resources:

For questions, contact us at LOCS@cdc.gov.

Thank you,

The Laboratory Outreach Communication System

Laboratory Outreach Communication System (LOCS) | Division of Laboratory Systems (DLS)

Center for Surveillance, Epidemiology, and Laboratory Services (CSELS)

Centers for Disease Control and Prevention (CDC)